secwatch.observer — SEC 8-K summary
======================================

Issuer:     AXIM BIOTECHNOLOGIES, INC. (AXIM)
CIK:        0001514946
Form:       8-K
Filed at:   2022-09-19T23:59:59+00:00
Accession:  0001096906-22-002280
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AXIM signs exclusive global licensing deal with Verséa for dry eye diagnostic tests
--------------------------------------------------------------------------------

- Five-year License and Distribution Agreement with Verséa for global sale of AXIM's point-of-care ocular diagnostics.
- Three tests included: IgE (allergy), Lactoferrin (dry eye), and MMP-9 (inflammation); IgE and Lactoferrin are FDA-cleared.
- Verséa plans to launch IgE and Lactoferrin tests at 2022 AAO and Optometry conferences; MMP-9 in 18–24 months.
- Verséa must meet annual minimum sales commitments; no upfront or milestone payments disclosed.
- CEO Huemoeller says deal marks transition from development-stage to revenue-generating healthcare organization.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1514946/000109690622002280/0001096906-22-002280-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1514946/000109690622002280/axim-20210915.htm
  HTML page:      https://secwatch.observer/filing/0001096906-22-002280

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer